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Objectives. The aim of the present study was to evaluate the 
effectiveness of prolonged administration fthrombolytic therapy 
with low doses of recombinant tissue-type plasminogen activator 
(rt-PA) in patients with refractory unstable angina. 
Background. Intracoronary thrombosis i often the cause of 
instability in patients with unstable angina. Thrombolytic therapy 
has been tested in these patients with conflicting results. 
Methods. Sixty-seven patients with unstable angina refractory 
to standard antianginal therapy were randomized to receive, in 
addition to the common antianginal therapy, either rt-PA 
(0.03 mg/kg body weight per h for 3 consecutive days) plus heparin 
(to achieve activated clotting time of 250 to 400 s) (36 patients, 
group A) or the same dose of heparin plus placebo (31 patients, 
group B). 
Results. No major bleeding was observed in either group of 
patients. One patient in group A and four in group B (2.7% vs. 
12.9%, p < 0.01) developed acute myocardial infarction during the 
hospital period. Eight patients in group B underwent emergency 
coronary artery surgery or angioplasty because of worsening of 
symptoms. Group A patients had a significant reduction in the 
occurrence of chest pain compared with those in group B (95% 
confidence interval -7.2 to -2.1 episodes/3 days, p < 0.01). 
Patients in group B had a greater number of episodes of transient 
myocardial ischemia (237 vs. 103, p < 0.01) and a longer total 
ischemic burden (114 -+ 23 vs. 45.6 -+ 8.9 min/day, p < 0.01) than 
group A patients. After a mean follow-up of 14 -+ 6 months, group 
A patients were more frequently angina free and had a lower 
incidence of readmission tothe hospital than group B patients. 
Conclusions. The combination of heparin and protracted ad- 
ministration of rt-PA at low doses is effective in stabilizing and 
reducing in-hospital adverse events in patients with unstable 
angina refractory to antianginal therapy. 
(J Am Coil Cardiol 1995;25:1295-9) 
Unstable angina is a syndrome that includes a broad spectrum 
of pathophysiologic conditions. The classifications used for 
unstable angina differentiate patients according to the severity 
of the chest pain and the clinical scenario but do not take into 
account the different pathologic substrates and therefore their 
different herapeutic needs (1). Coronary angiography and 
coronary angioscopy have shown intracoronary thrombosis n a 
sizable proportion of patients with unstable angina, although 
the real incidence of intracoronary thrombosis in the different 
patient subsets is still under debate (2-12). However, a high 
incidence of coronary artery thrombosis (90%) has been 
documented bycoronary angioscopy inpatients with angina t 
From the Department of Cardiology University of Catania, Catania; *De- 
partment of Basic and Clinical Medicine, University of Reggio, Calabria; 
tDepartment ofCardiology,, University La Sapienza, Rome; and ~:Department of 
Medicine, G. lazzolino Hospital, Vibo Valentia, Italy. This study was supported 
by a grant from Boehringer lngelheim, Firenze, Italy. 
Manuscript received April 25, 1994; revised manuscript received December 
15, 1994, accepted January, 4, 1995. 
Address for correspondence: Dr. Giuseppc M. C. Rosano, Istituto di 
Cardiologia, Universita' Cattolica del Sacro Cuore, Policlinico Agostino Gemelli, 
Largo A. Gemelli, 8, 00168 Rome, Italy. 
rest (10). Furthermore, an alteration of the coagulation profile 
and high plasma levels of plasminogen activator inhibitor 
(PAI)-I have frequently been found in patients with unstable 
angina (13,14). 
In contrast to acute myocardial infarction, where the patho- 
genetic mechanism is the abrupt occlusion of a coronary artery, 
in unstable angina the imbalance of the thrombolytic state lasts 
for several days, causing formation and lysis of intracoronary 
thrombi. Therefore, systemic thrombolysis, which is highly 
effective in patients with acute myocardial infarction, may not 
be as effective in patients with unstable angina if administered 
at the same dosage used for patients with acute myocardial 
infarction because it may trigger thrombus formation as a 
result of production of thrombogenic substances. 
The aim of the present study was to assess the effectiveness 
of thrombolytic therapy with recombinant tissue-type plasmin- 
ogen activator (rt-PA) in the subset of patients with unstable 
angina refractory to maximal antianginal therapy, who are the 
most likely to have intracoronary thrombus. Because of the 
subacute, quite long-lasting nature of intracoronary thrombo- 
sis in this syndrome, patients underwent thrombolysis n low 
dose for a prolonged period of time. 
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Methods  
Patients. The study included 163 consecutive patients 
(mean age 58 + 8 years, range 38 to 68) with the clinical 
diagnosis of unstable angina who were eligible for thrombolysis 
(Thrombolysis n Myocardial Infarction trial criteria). Unsta- 
ble angina was defined as crescendo angina (more frequent, 
severe, longer in duration or precipitated by distinctly less 
effort than previously) or angina at rest, or both. All patients 
had reversible electrocardiographic (ECG) changes during 
pain (ST segment horizontal or downward depression or 
elevation >1 mm at 0.06 s from the J point, T wave pseudo- 
normalization). Patients with acute myocardial infarction in 
the previous 2 weeks, significant rest ECG abnormalities that 
would interfere with the interpretation of the ST segment 
changes, left or right bundle branch block, second-degree or
higher atrioventricular block, left ventricular hypertrophy, 
systolic blood pressure >200 mm Hg, symptomatic heart 
failure, cerebrovascular disease or congenital heart disease or 
patients who required emergency percutaneous coronary an- 
gioplasty or cardiac surgery were excluded from the study. 
Acute myocardial infarction was excluded in all patients by 
serial enzymatic and ECG tests. Serum creatine kinase (CK)- 
MB isoforms were checked every 3 h during the first 2 days 
after admission and every 6 h thereafter until completion of 
the study protocol. All patients were started on intravenous 
nitroglycerin (5 to 10 #g/kg per rain), beta-adrenergic-blocking 
agents (atenolol, 100 rag/day) or calcium antagonists (dilti- 
azem 360 rag/day), or both, and aspirin. 
Study protocol. Patients whose condition did not stabilize 
after at least 24 h of maximal medical therapy entered a 
double-blind placebo-controlled study of rt-PA plus heparin 
versus heparin alone. Stabilization was defined as the absence 
of further episodes of chest pain at rest or a reduction >30% 
in the number of episodes of chest pain during the first 24 h of 
the hospital period, or both, compared with that in the 24 h 
before admission. Sixty-seven patients entered the study and 
were randomized to receive rt-PA (20-rag bolus plus 
0.03 mg/kg per h) (Actilyse, Boehringer Ingelheim, Firenze, 
Italy) plus intravenous heparin or intravenous heparin plus 
placebo (bolus plus infusion) for 3 consecutive days. Heparin 
infusion was started with a 5,000-IU bolus followed by 
1,000 IU/h. The infusion rate was then adjusted to keep the 
activated clotting time between 250 and 400 s. Treatment was 
initiated within 36 h of admission, while patients were receiving 
maximal antianginal therapy, which was continued throughout 
the study. Patients were continuously monitored uring the 
three study days and were then kept in the hospital to monitor 
recurrence of chest pain for at least one more week. Supervis- 
ing physicians and hospital staff were unaware of the study 
drug. Primary end points of the study were the clinical 
stabilization of patients (concealment or reduction of angina to 
previous stable levels) during the three study days and the 
presence of transient myocardial ischemia on ambulatory ECG 
monitoring during the last 48 h of treatment. Secondary end 
points were clinical stabilization during the hospital period, 
transient myocardial ischemia on ambulatory ECG monitoring 
during the last 48 h of the hospital period and exercise-induced 
myocardial ischemia t predischarge exercise test. The devel- 
opment of acute myocardial infarction or ventricular fibrilla- 
tion was considered a failure of treatment and allowed the 
physician to break the randomization code. 
Holter monitoring. All patients underwent continuous 
Holter monitoring for at least 48 h during the last 2 days of trial 
treatment and at days 6 and 7 after entering the trial. Patients 
who developed acute myocardial infarction during the Holter 
monitoring were excluded from the analysis. The Holter 
recordings were performed using the two leads that had shown 
the most pronounced ischemic hanges on the standard 12- 
lead ECG during a painful episode. Patients were carefully 
instructed to press the event marker button during angina nd, 
when possible, to record the time in a diary. The Holter tapes 
were replaced every 24 h to complete the 48 h of recording. 
The recordings were analyzed by two experienced investigators 
uninformed of the clinical data. The frequency response of 
these recordings was 0.05 to 100 Hz and was in agreement with 
the American Heart Association specifications for the ST 
segment changes. A downward or horizontal depression or an 
elevation >1 mm of the ST segment from the baseline at 0.08 s 
from the J point, gradually arising and lasting for at least 60 s, 
was considered significant for transient myocardial ischemia. 
The data from the Holter monitoring were compared with 
patient diaries or with the coronary care unit report o evaluate 
whether the ischemic episodes were silent or symptomatic. 
Exercise testing. All patients underwent a symptom- 
limited exercise test off therapy at discharge using the modified 
Bruce protocol. The exercise test was stopped at the point of 
attainment of predicted maximal heart rate, severe fatigue, 
worsening angina, ST segment depression >3 ram, systolic 
blood pressure >230 mm Hg or a decrease in systolic blood 
pressure >20 mm Hg or complex ventricular arrhythmia 
(Lown class ->3). The level of ST segment depression at 60 ms 
after the J point was calculated by a computer-assisted system 
in all 12 leads. Downsloping or horizontal ST segment depres- 
sion > 1 mm occurring at 60 ms after the J point was consid- 
ered significant. 
Follow-up. Patients were followed up at 3-month intervals 
to ascertain their health status during a mean follow-up 
duration of 14 + 6 months. Description of causes and circum- 
stances of death were obtained from physicians, hospital 
records and coroner eports. 
Data analysis. Statistical significance in the incidence of 
successful and failed outcomes were tested using the chi- 
square analysis. The Wilcoxon test was used to analyze differ- 
ences in continuous variables. Data are expressed as mean 
value _+ 1 SD; p < 0.05 was considered significant. 
Results 
Sixty-seven of the 163 patients (60 men, 7 women; mean 
[_+SD] age 57 _+ 8 years, range 43 to 68) met the inclusion 
criteria for the study, 36 of whom were randomized toreceive 
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Table l. Baseline Clinical Characteristics of Patients Allocated to 
Receive Either Heparin Plus Recombinant Tissue-Type Plasminogen 
Activator or Heparin Plus Placebo 
rt-PA Placebo 
01=36) (n 31) 
Age (yr) 57 + 9 58 ~ 8 
Gender (M/F) 32/4 28/'3 
Heart rate (beats/rain) 69 + 15 71 _+ 12 
Blood pressure (mm Hg) 162 + 22 lb0 + 18 
Risk factors for CAD 
Family history 19 21 
Diabetes 6 4 
Cigarette smokers 27 25 
Hypertension 12 1 I 
Hypercholesterolemia 8 7 
Previous myocardial infarction lil 0 
Unstable angina 
Crescendo angina 25 23 
Angina at rest 34 26 
Clotting indexes at admission 
ACT (s) 84 + 12 78 ± 15 
Fibrinogen (rag/100 ml) 236 + 25 241 ± 31 
APTI  (s) 25 ± 0.7 24 _+ 1 
ECG changes during pain 
ST segment changes 29 26 
T wave changes 13 III 
CAD 
l-vessel 6 7 
2-vessel 11 14 
3-vessel 5 6 
Antianginal medications 
Nitrates 36 31 
Calcium channel blockers 36 31 
Beta-blockers 32 29 
Data presented are mean value + 1 SD or number of patients. ACT = 
activated clotting time; APTF = activated partial thromboplastin time; CAD = 
coronary artery disease; ECG = electrocardiographic; F - female; M = male; 
rt-PA - recombinant tissue-type plasminogen activator. 
rt-PA plus heparin (group A) and 31 to receive heparin plus 
placebo. The baseline characteristics of the two groups of 
patients are shown in Table 1. The two groups were similar 
with regard to clinical characteristics, use of cardiac medica- 
tions and extent of coronary artery disease. One patient in 
group A developed an acute myocardial infarction during the 
first 12 h of treatment and was therefore treated with a 
standard tbrombolytic regimen, and four patients in group B 
interrupted the placebo infusion (two at day 2 and two at day 
3) because of worsening of symptoms associated with the 
development of acute myocardial infarction. The time delay 
between the most recent episode of angina associated with 
reversible ECG changes and the initiation of study drug was 
18 min. Patients receiving rt-PA showed a significant reduction 
in the occurrence of chest pain compared with those receiving 
heparin alone (95% confidence interval -7.2 to -2.1 epi- 
sodes/3 days, p < 0.01). Patients receiving heparin alone had a 
significantly greater number of episodes of transient myocar- 
dial ischemia on ambulatory ECG monitoring and a longer 
total ischemic burden than patients receiving heparin and 
rt-PA, both during the treatment phase and at predischarge 
ambulatory ECG monitoring (Table 2). Patients in group B 
also more frequently had a positive exercise test at low work 
load and a greater extent of ST segment depression at dis- 
charge (Table 2). During the hospital period, patients in group 
B had recurrence ofangina or worsening of symptoms, or both, 
that required emergency intervention (angioplasty or coronary 
surgery) more frequently than group A patients (Table 3). 
Patients receiving heparin alone also had a greater incidence of 
cardiac-related vents during the hospital period or during 
follow-up, or both. Forty-nine patients (22 in the rt-PA-treated 
group and 27 in the heparin group) underwent selective 
coronary angiography and left ventriculography within 3 
months of hospital admission. During follow-up, group A 
patients were more frequently angina free and had a lower 
incidence of hospital admissions for unstable angina or acute 
myocardial infarction than group B patients (Table 3). The 
majority of adverse vents in both groups occurred within 3 
months of hospital discharge. 
Discuss ion 
The results of the present study show a clear clinical benefit 
of protracted thrombolysis in patients with unstable angina. 
Patients receiving heparin and rt-PA showed better clinical 
stabilization, a more favorable short-term prognosis and a 
lower incidence of transient episodes of myocardial ischemia. 
These results clearly show that the combination of prolonged 
tbrombolysis with low dose rt-PA and the usual antianginal 
therapy can restore the clinical status of patients with refrac- 
tory unstable angina. The effect of prolonged thrombolysis may 
be dependent on an improvement of the local coronary 
situation, as suggested by a lower incidence of episodes of 
transient myocardial ischemia on ambulatory ECG monitor- 
ing. The effectiveness of prolonged low dose thrombolysis on 
transient myocardial ischemia found in this study is in keeping 
with recent findings by Gold et al. (15), who produced a 
significant reduction in the episodes of angina by prolonged 
infusion of rt-PA (12 h) in patients with unstable angina. 
Intracoronary thrombosis n unstable angina. The benefi- 
cial effect suggested by the present study may be dependent on 
an effect of prolonged rt-PA administration intracoronary 
thrombosis, which is thought o be the primary cause of 
instability in patients with unstable angina (5-12). The preva- 
lence of intracoronary thrombus among patients with unstable 
angina is difficult o determine because of the different inclu- 
sion criteria and the different methods used in various studies 
(8-12). Recent angioscopic studies (11) have shown that 
patients with unstable angina have a high incidence of intra- 
coronary thrombosis and that the thrombus i often different in 
composition and evolution than that in myocardial infarction. 
The thrombus found in patients with unstable angina is often 
grayish-white in color and nonobstructing of the lumen or 
obstructing it for a short period of time, suggesting that the 
thrombotic process is subacute and often long lasting (10,11). 
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Table 2. Electrocardiographic Findings for 67 Patients During Treatment and at Discharge 
rt-PA Placebo p 
(n = 35) (n = 27) Value 
Ambulatory ECG monitoring day 2-3 
No. of episodes 
No. of patients with ST 
Mean TIB/day (min) 
TIB >60 min/day 
Episodes of ST ~/paticnt per day 
Episodes of silent ischcmia/patient per day 
Median duration of episodes (min) 
Median duration of silent episodes (min) 
Ambulatory ECG monitoring day 6 7 
No. of episodes 
No. of patients with ST ,~ 
Mean TIB/day (rain) 
Episodes of ST ~,/patient per day 
Episodes of silent ischemia/patient per day 
Median duration of episodes (min) 
Median duration of silent episodes (rain) 
Predischarge exercise test 
Positive 
Positive at low work load (<stage 3) 
Mean ST segment depression (mm) 
Time to 1 mm 
Rate-pressure product at 1 mm ST , 
103 237 < 0.01 
21 24 < 0.05 
45.6 _+ 8.9 114 _+ 23 <0.01 
3 6 
4.9 _+ 1.7 9.9 _+ 2.7 < 0.01 
2.3 + 0.8 4.2 _+ 1.3 < 0.0l 
14 21 
15.4 16.6 
29 187 < 0.01 
12 25 < 0.01 
15.3 + 12 123 _+ 38 < 0.01 
2.4 _+ 1).9 7.5 + 2.1 < 0.01 
1.6 _+ 0.3 4.1 _+ 1.9 < 0.01 
5 18 
6 24 
32/32 19/19 
2 7 < 0.02 
1.3 + 0.4 1.8 _+ 0.4 < 0.02 
486 + 27 390 _+ 74 < 0.01 
22,735 + 3,564 18,650 _+ 2,758 < 0.05 
Data presented are mean value + 1 SD or number of patients. ST $ = ST segment depression; TIB = total ischemic 
burden; other abbreviations as in Table 1. 
Lablanche et al. (11) recently showed that patients with angina 
at rest are more likely to have intracoronary thrombus than 
patients with crescendo angina stabilized by maximal standard 
Table 3. Events in the Recombinant Tissue-Type Plasminogen 
Activator and Placebo Groups During the Hospital Period and at 
Fol low-Up 
P 
rt-PA Placebo Value 
In hospital 
Patients 36 31 
Major bleeding I! 0 
Recurrent angina (CCS >II) 5 13 < 0.03 
Acute myocardial infarction 1 4 
Emergency CABG or PTCA i! 8 </I.(1! 
Ventricular fibrillation II 2 
Killip class ->3 1 5 
Cumulative adverse events 7 21 < 0.01 
(patients) 
Follow-up 
Patients 35 23 
Deaths 3 4 
Hospital admission for AMI or 7 1 l < 0.05 
UA 
CABG or PTCA 20 18 
Angina free on thera W 8 l < 0.01 
Data presented are number of patients. AMI - acute myocardial infarctionl 
CABG - coronary artery bypass graft; CCS = Canadian Cardiovascular Society; 
PTCA - percutaneous transluminal coronary angioplasty; rt-PA = recombinant 
tissue-type plasminogen activator; UA = unstable angina. 
antianginal therapy. We recently showed (12) that the inci- 
dence of intracoronary thrombosis is greater in patients with 
unstable angina not stabilized by antianginal therapy than in 
those whose angina does stabilize. Therefore, the patients 
included in the present study had high probability of having 
coronary artery thrombosis and thus of benefiting from throm- 
bolysis. Because of the subacute nature of the syndrome, 
thrombolytic therapy given as in acute myocardial infarction 
may be unsuitable if not detrimental in patients with unstable 
angina because the drug would be effective for only a limited 
period of time and would generate thrombin degradation 
products that could enhance thrombosis. In the present study 
the dosage of the drug took into account the long-lasting 
imbalance of clot formation and lysis of the syndrome and the 
need to avoid large production of thrombin degradation 
products. 
Previous studies. Several studies have tested the effective- 
ness of thrombolytic therapy in patients with unstable angina. 
The results of the different studies are not homogeneous, 
mainly because of the different inclusion criteria and subset of 
patients studied. Therefore, a definite answer to the question 
has not yet been provided (15-20). Freeman et al. (18) showed 
a significant reduction of intracoronary thrombosis after rt-PA 
compared with that after placebo in patients with unstable 
angina. Gold et al. (15) showed a significant reduction in 
angina in patients with unstable angina treated with heparin 
and prolonged infusion of rt-PA (12 h) compared with patients 
treated with placebo. These findings were not confirmed by 
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Neri Serneri et al. (21), who did not find a sustained reduction 
in the episodes of myocardial ischemia on Holter monitoring in 
patients treated with rt-PA alone for 12 h. The finding that in 
this study rt-PA administration was not associated with hepa- 
rinization may explain the discrepancies between these two 
studies. Recent studies (19,20) that used standard thrombolytic 
regimens have not demonstrated any beneficial effect of 
thrombolysis on long-term prognosis of patients with unstable 
angina. The reasons for the discrepancy between the present 
study and the TIMI IIIB (20) study or the Unstable Angina 
Study Using Eminase (UNASEM) (19) study are likely to be 
dependent on patient selection and dosage of thrombolysis. 
Important points of discrepancy between the present study and 
the UNASEM study are the drug used and the primary end 
points, which in the latter study were the cardiac events during 
follow-up. In our view, thrombolysis should be used just to 
stabilize patients with unstable angina for further diagnostic 
and therapeutic procedures and, therefore, must not be con- 
sidered in most patients a definitive therapy that may justify a 
long-term follow-up. 
Thrombolysis as a bridge toward further therapeutic inter- 
ventions. Despite the beneficial effect of thrombolysis shown 
in the present study, thrombolytic therapy cannot be consid- 
ered a definite solution for patients affected by unstable angina 
but should be considered a useful temporary integration of the 
standard antianginal therapy and a bridge toward the next step 
in the diagnosis and therapy of these patients. Indeed, >75% 
of our patients underwent coronary artery surgery or angio- 
plasty during 1 year of follow-up. Despite this high incidence of 
revascularization procedures, the follow-up data suggest hat 
the benefit of prolonged thrombolysis with low dose rt-PA 
persists for several months. 
Study limitations. The major limitation of the present 
study is the lack of angiographic data documenting the effects 
of the prolonged infusion of rt-PA. However, the present study 
was mainly designed to evaluate the effectiveness of thrombol- 
ysis on the clinical status and the occurrence of transient 
episodes of myocardial iscbemia. Therefore, further studies are 
needed to confirm the results of the present study and to assess 
the effectiveness of this treatment on angiographic variables. 
Conclusions. Prolonged infusion of low dose rt-PA plus 
heparin is more effective than heparin alone to stabilize 
patients with unstable angina refractory to maximal antianginal 
therapy. The addition of thrombolysis to standard antianginal 
therapy may represent a useful temporary integration for a 
safer utilization of further diagnostic and therapeutic proce- 
dures. 
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